Stephanie Graff, MD, FACP, FASCO (@DrSGraff) ranks #7 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 73 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: VIKTORIA-1, BRIDGET, SWITCH. CMS Open Payments lists $12,560 in 2025 general payments.
At a Glance
- 12 posts naming a trial in 2026
- 11 trials discussed by name
- Breast Cancer: US #7, Global #9 · 73 physicians engaged
- Leading physician voice: #2 of 11 physicians on KEYNOTE-522
- CMS Open Payments lists $12,560 in 2025 general payments.
This Month
What Stephanie Graff, MD, FACP, FASCO has posted in the last 30 days. Updated November 10, 2026.
BRIDGET 🧠 @drsarahsam ❓does adding tucatinib to HP or TDM1 after isolated CNS progression improve IC-PFS in HER2+MBC 12mo IC-PFS = 64% 18mo IC-PFS=59% #ESMO26 @OncoAlert https://t.co/7iuThBVgqC
Switch w/TOP1i-ADCs had limited efficacy in TOP1i-based ADC-refractory HER2-neg MBC 🔹ORR 0-8.3% 🔹Median PFS 1.4-3.0 mos 🧬Preliminary biomarkers work suggest ATM mut as a potential predictor of response #ESMO26 @OncoAlert https://t.co/dF7H5HYOQz
Overall survival from phIII postMONARCH trial of abemaciclib + fulvestrant v placebo + fulv for HR+ HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy https://t.co/hYJPDj1XzG #ESMO26 @OncoAlert @KalinskyKevin @Annals_Oncology
Bill Gradishar also opens a thoughtful cross trial comparison as discussing EvERA. #ESMO26 @OncoAlert https://t.co/XhD7BDlhyC
VIKTORIA-1 shows benefit of Gedatolisib + fulvestrant +/- palbociclib significantly improved median PFS across subgroups as compared to alpelisb+fulv (in second line after CDK4/6i) #ESMO26 @OncoAlert @BarbaraPistill2 https://t.co/ItKZeazGji
Bill Gradishar poses appropriate questions discussing VIKTORIA-1 #ESMO26 @OncoAlert https://t.co/4jwW7AA8c2
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Stephanie Graff, MD, FACP, FASCO
Physicians who reposted Stephanie Graff, MD, FACP, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #7 | #9 | 73 | 122 | Full ranking |
What Colleagues Are Saying About Stephanie Graff, MD, FACP, FASCO
2026 posts by fellow physicians that mention @DrSGraff, quoted word for word.
1. Requested for “the other brother” to be “edited” out… but @ASCO and my parents insisted I behave. 2. Our annual mentorship session with @DrSGraff 🙏🏽🙏🏽 3. Besides the data at ASCO… getting to see friends and colleagues from around the world @drshieldsmd @weoncologists @GlopesMd @RManochakian @YAbdouMD
Trials Stephanie Graff, MD, FACP, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| VIKTORIA-1 | 2 | #6 of 23 | Oct 24, 2026 |
| BRIDGET | 1 | #10 of 17 | Oct 26, 2026 |
| SWITCH | 1 | #11 of 23 | Oct 26, 2026 |
| postMONARCH | 1 | #7 of 18 | Oct 24, 2026 |
| EVERA | 1 | #8 of 30 | Oct 24, 2026 |
| TROPION-Breast02 | 1 | #10 of 26 | Oct 24, 2026 |
| HORIZON-Breast06 | 1 | #5 of 15 | Oct 23, 2026 |
| TALENT (TRIO-US B-12) | 1 | #6 of 23 | Oct 23, 2026 |
| NATALEE | 1 | #33 of 46 | Oct 23, 2026 |
| ASCENT-04 | 1 | #6 of 24 | May 31, 2026 |
| KEYNOTE-522 | 1 | #2 of 11 | May 30, 2026 |
Stephanie Graff, MD, FACP, FASCO on VIKTORIA-1
VIKTORIA-1 shows benefit of Gedatolisib + fulvestrant +/- palbociclib significantly improved median PFS across subgroups as compared to alpelisb+fulv (in second line after CDK4/6i) #ESMO26 @OncoAlert @BarbaraPistill2 https://t.co/ItKZeazGji
Bill Gradishar poses appropriate questions discussing VIKTORIA-1 #ESMO26 @OncoAlert https://t.co/4jwW7AA8c2
Stephanie Graff, MD, FACP, FASCO on BRIDGET
BRIDGET 🧠 @drsarahsam ❓does adding tucatinib to HP or TDM1 after isolated CNS progression improve IC-PFS in HER2+MBC 12mo IC-PFS = 64% 18mo IC-PFS=59% #ESMO26 @OncoAlert https://t.co/7iuThBVgqC
Stephanie Graff, MD, FACP, FASCO on SWITCH
Switch w/TOP1i-ADCs had limited efficacy in TOP1i-based ADC-refractory HER2-neg MBC 🔹ORR 0-8.3% 🔹Median PFS 1.4-3.0 mos 🧬Preliminary biomarkers work suggest ATM mut as a potential predictor of response #ESMO26 @OncoAlert https://t.co/dF7H5HYOQz
Stephanie Graff, MD, FACP, FASCO on postMONARCH
Overall survival from phIII postMONARCH trial of abemaciclib + fulvestrant v placebo + fulv for HR+ HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy https://t.co/hYJPDj1XzG #ESMO26 @OncoAlert @KalinskyKevin @Annals_Oncology
Stephanie Graff, MD, FACP, FASCO on EVERA
Bill Gradishar also opens a thoughtful cross trial comparison as discussing EvERA. #ESMO26 @OncoAlert https://t.co/XhD7BDlhyC
Stephanie Graff, MD, FACP, FASCO on TROPION-Breast02
TROPIONBreast02 DatoDXd vs TPC chemo in 1L mTNBC brain Mets analysis by @RebeccaDSing Allowed treated or untx + asymptomatic brain mets (n=61) Intracranial response 62.5% vs 37.5% w/ durable benefit at 12 weeks 75% vs 50% #ESMO26 @OncoAlert https://t.co/HguoAefquz
Stephanie Graff, MD, FACP, FASCO on HORIZON-Breast06
HORIZON-Breast06 confirms benefit of trastuzumab *rezetecan* in a DB06-like patient population—HER2low, chemo-naive #ESMO26 @OncoAlert https://t.co/oQ56NjDGq4
Stephanie Graff, MD, FACP, FASCO on TALENT (TRIO-US B-12)
TALENT—neoadj TDXd (6-8 cycles) +/- AI in HER2 low HR+ early stage breast ca ypCR // RCB TDXd 7% // 16% T-DXd/AI: 3% // 9% T-DXd→ TC: 17% // 17% Author concludes “modest” benefit; I would say “disappointing”. ypCR just isn’t the same endpoint w/ ER+ disease #ESMO26 @OncoAlert https://t.co/3jg6NTqiyH
Stephanie Graff, MD, FACP, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
FourLight shows 1st CDK4i Atirmociclib after CDK4/6i shows significant improvement in mPFS 9.4 vs 6.6 mos HR=0.60 notable AE neutropenia #ESMO26 @OncoAlert https://t.co/1z1a5CkDFq
Great conclusion slide summarizing the long term follow-up of NSABP-42 w/ extended AI (letrozole) #ESMO26 @OncoAlert https://t.co/z3ix2C7fdT
Further evidence for the CNS efficacy of TDXd from DB09 and @CristinaSaura3 #ESMO26 @OncoAlert https://t.co/rYeJpNyD2B
FINER demonstrates ipatasertib + fulvestrant improves PFS (but not OS) for both ITT and AKT pathway altered cohorts with notable AEs #ESMO26 @OncoAlert https://t.co/3SzRMFV2ew
The age of resistance monitoring has arrived. ctDNA + camizestrant enter the ER+ metastatic breast cancer pathway. https://t.co/JSq6SjRCPA
Industry Payments
CMS Open Payments · 2025 general payments
$12,560 across 42 payments